Eyenovia (EYEN) Releases Earnings Results, Misses Estimates By $0.06 EPS

Eyenovia (NASDAQ:EYEN) posted its quarterly earnings results on Wednesday, May 9th. The company reported ($0.45) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.06), Morningstar.com reports.

Shares of Eyenovia traded down $0.22, hitting $8.27, during trading on Friday, Marketbeat reports. The company’s stock had a trading volume of 5,300 shares, compared to its average volume of 17,017. The company has a market cap of $84.07 million and a price-to-earnings ratio of -3.78. Eyenovia has a fifty-two week low of $7.32 and a fifty-two week high of $10.74.

Several hedge funds have recently modified their holdings of EYEN. Uniplan Investment Counsel Inc. acquired a new position in shares of Eyenovia during the first quarter worth $3,248,000. Sabby Management LLC acquired a new position in shares of Eyenovia during the first quarter worth $908,000. Millennium Management LLC acquired a new position in shares of Eyenovia during the first quarter worth $2,525,000. Finally, Highbridge Capital Management LLC acquired a new position in shares of Eyenovia during the first quarter worth $1,373,000. Hedge funds and other institutional investors own 0.07% of the company’s stock.

Several research firms have commented on EYEN. Ladenburg Thalmann began coverage on shares of Eyenovia in a research note on Tuesday, February 20th. They issued a “buy” rating and a $35.00 price target for the company. Roth Capital began coverage on shares of Eyenovia in a research note on Tuesday, February 20th. They issued a “buy” rating and a $20.00 price target for the company. Zacks Investment Research upgraded shares of Eyenovia from a “hold” rating to a “buy” rating and set a $9.75 price target for the company in a research note on Tuesday, April 24th. Finally, ValuEngine upgraded shares of Eyenovia from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd.

Eyenovia Company Profile

Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst that has completed Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat that has completed Phase II clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia.

Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply